International Clinical Trials Day marked
20 May 2015
Melinda Paton would not be alive today without MIA. Over three years ago, Melinda was told she had only nine months to live due to her stage four melanoma diagnosis. After being transferred to MIA she was placed on an Anti-PD-1 clinical trial.
"I started the Anti-PD-1 trial in September and by December 2013; my tumour had gone from the bowel. When I saw the scan, I was in complete disbelief; I couldn’t believe that it had just disappeared,” says Melinda.
“When I first met with Dr Georgina Long, as a stage 4 patient, the tumour was causing me a lot of pain and I was very weak. The tumours were progressing very quickly and I had surgery in December to have a lymph node removed. After this is when I went onto PD-1, where I noticed a difference almost immediately.
“With PD-1, I don’t have any pain, I’m not tired, and I don’t feel sick. I work full time and it lets me live as normal life as possible. The access to these drugs has been lifesaving, without them there is no doubt I would have died a long time ago.”
Melinda is benefiting from Anti-PD1 immunotherapy treatments and she is able to live as normal life as possible. It is thanks to dedicated clinicians that have discovered these clinical trials that are saving patients lives and improving cancer care globally.
There is still more work to be done. Donate now.
A landmark study led by MIA's Dr Willmott is making a difference to melanoma treatment around the globe.
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.
The uniquely Aussie awareness campaign ‘Game On Mole’ is back for its second year – with a new look but same important message.
Professor Richard Scolyer receives The Royal College of Pathologists of Australasia Distinguished Fellow Award.
Professor Long cites as a highlight of her 2-year Presidency, the phenomenal research output by SMR members who have continued to lead the cancer field despite the impact of COVID-19.
Join in the fun of the virtual event, and together we can run over melanoma!
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.
Participate in our online survey and help us understand the support needs of melanoma patients and carers.
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.
In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
“I had a complete response within about six months. All of my tumours disappeared."
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.